Cosmo Pharmaceuticals N.V.

Informe acción SWX:COPN

Capitalización de mercado: CHF1.2b

Salud financiera de hoja de balance de Cosmo Pharmaceuticals

Salud financiera controles de criterios 5/6

Cosmo Pharmaceuticals tiene un patrimonio de accionistas total de €433.6M y una deuda total de €559.0K, lo que sitúa su ratio deuda-patrimonio en 0.1%. Sus activos y pasivos totales son €554.0M y €120.3M respectivamente. El BAIT de Cosmo Pharmaceuticals es de €12.2M, por lo que su ratio de cobertura de intereses es de 2.7. Tiene efectivo e inversiones a corto plazo que ascienden a €50.3M.

Información clave

0.1%

Ratio deuda-patrimonio

€559.00k

Deuda

Ratio de cobertura de intereses2.7x
Efectivo€50.28m
Patrimonio€433.63m
Total pasivo€120.35m
Activos totales€553.98m

Actualizaciones recientes sobre salud financiera

Recent updates

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

May 20
Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

Apr 03
Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Mar 07
When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

What Kind Of Investors Own Most Of Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Feb 01
What Kind Of Investors Own Most Of Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€102.2M) de COPN superan a sus pasivos a corto plazo (€23.2M).

Pasivo a largo plazo: Los activos a corto plazo de COPN (€102.2M) superan a sus pasivos a largo plazo (€97.2M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: COPN tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de COPN ha pasado de 35% a 0.1% en los últimos 5 años.

Cobertura de la deuda: La deuda de COPN está bien cubierta por el flujo de caja operativo (6014.8%).

Cobertura de intereses: Los pagos de intereses de la deuda de COPN no están bien cubiertos por el BAIT (2.7x cobertura).


Hoja de balance


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target